Live
- 11 lakh BPL cards revoked, claims K’taka BJP
- Exit polls results indicated victory of the NDA government in Maharashtra and Jharkhand!
- Deputy CM Bhatti Vikramarka Reviews SC/ST Development Funds Implementation
- AP cabinet approves key decisions, check here
- Maharashtra records 58.22 pc turnout, Independent candidate dies of heart attack in Beed
- Manipur: Mobile internet suspension extended for 3 days in 7 districts, curfew relaxed in 4 districts
- EPFO adds 18.8 lakh members in September as employment rises
- ‘Criticise me, not Rabindranath Tagore’, says Assam CM on renaming Karimganj
- Bihar govt launches Ayushman Vandan Scheme
- Infighting again erupts in Trinamool on chair of West Bengal Medical Council
Covaxin effective against Delta Plus
Covaxin effective against Delta Plus
Bharat Biotech's Covid-19 vaccine Covaxin (BBV152) is effective against Delta Plus (AY.1) variant of the coronavirus, according to a study published in bioRxiv by the Indian Council of Medical and Research (ICMR).
Hyderabad: Bharat Biotech's Covid-19 vaccine Covaxin (BBV152) is effective against Delta Plus (AY.1) variant of the coronavirus, according to a study published in bioRxiv by the Indian Council of Medical and Research (ICMR).
"Here, we have evaluated the IgG antibody titer and neutralizing potential of sera of Covid-19 naive individuals full doses of BBV152 vaccine, Covid-19 recovered cases with full dose vaccines and breakthrough cases post-immunization BBV152 vaccines against Delta, Delta AY.1 and B.1.617.3.," the study said.
The recent emergence of the SARS-CoV-2 Variant B.1.617.2 (Delta) variant with its high transmissibility has led to the second wave in India.
Covaxin, a whole-virion inactivated SARS-CoV-2 vaccine used for mass immunization in the country, showed a 65.2 per cent protection against the Delta variant in a double-blind, randomized, multicentre, phase 3 clinical trial.
Subsequently, Delta has further mutated to Delta AY.1, AY.2, and AY.3.
Of these, AY.1 variant was first detected in India in April 2021 and subsequently from 20 other countries as well, the study said. The study is a pre-print and has not been peer reviewed.
